English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

HIV-infected individuals are at higher risk for cardiovascular disease (CVD) compared with the general population [1]. This increased risk is exponentially greater in older HIV-infected persons [1]. Given that the survival rate of the HIV-infected population is nearing that of the general population with the widespread use of highly effective antiretroviral treatment (ART), there is growing concern that the risk of CVD will be magnified several-fold as this aging group continues to increase in prevalence. Thus, therapies to address this risk for CVD in older patients are needed.

aids

A randomized, placebo-controlled pilot trial of N-acetylcysteine on oxidative stress and endothelial function in HIV-infected older adults receiving antiretroviral treatment